Stereoselective Covalent Destabilizing Degradation of the Oncogenic Transcription Factor MYC

Patent Status

Patent Pending

Brief Description

The oncogenic transcription factor MYC is implicated in a vast number of human cancers, yet it has proven exceptionally difficult to target using conventional small-molecule inhibitors due to its intrinsically disordered nature. This innovation, developed by UC Berkeley researchers, addresses the urgent need for a novel therapeutic strategy by introducing a class of compounds and pharmaceutical compositions that achieve the stereoselective covalent destabilizing degradation of the MYC protein.

Suggested uses

• To treat cancers driven by the MYC oncogene.

• As a pharmaceutical composition for degrading the oncogenic transcription factor MYC.

• For the development of small-molecule therapeutics that target historically "undruggable" proteins.

Advantages

• Achieves rapid and potent degradation of the MYC protein, offering a more complete therapeutic effect than mere inhibition.

• Uses a covalent, stereoselective mechanism for degradation, providing high specificity and potentially lower off-target effects compared to non-covalent inhibitors.

• Represents a novel therapeutic strategy to directly target MYC in cancers where traditional small-molecule inhibition has failed.

• Compounds are suitable for formulation into pharmaceutical compositions for clinical use.

Related Materials